EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium.

EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium.

NYVAC-C (vP2010), a recombinant vector expressing HIV subtype C gag, pol, env and nef antigens, was tested in a phase I study in healthy, HIV negative volunteers in London and Lausanne. Twenty-four participants were randomised to receive NYVAC-C (20) or matching placebo (4) at weeks 0 and 4, and ass...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Bart, P, Goodall, R, Barber, T, Harari, A, Guimaraes-Walker, A, Khonkarly, M, Sheppard, N, Bangala, Y, Frachette, M, Wagner, R, Liljeström, P, Kraehenbuhl, J, Girard, M, Goudsmit, J, Esteban, M, Heeney, J, Sattentau, Q, McCormack, S, Babiker, A, Pantaleo, G, Weber, J
Formaat:	Journal article
Taal:	English
Gepubliceerd in:	2008

Gelijkaardige items

Fostering e-learning in medical education: the EuroVacc team experience
door: Guilherme Andrade Marson, et al.
Gepubliceerd in: (2007-01-01)

Fostering e-learning in medical education: the EuroVacc team experience
door: Guilherme Andrade Marson, et al.
Gepubliceerd in: (2007-01-01)

A functional human IgM response to HIV-1 Env after immunization with NYVAC HIV C.
door: Sheppard, N, et al.
Gepubliceerd in: (2007)

Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors.
door: Esther D Quakkelaar, et al.
Gepubliceerd in: (2011-02-01)

rAd5/NYVAC-B is superior to NYVAC-B/rAd5 and is dependent on rAd5 dose for neutralizing antibody responses against HIV-1
door: Montefiori DC, et al.
Gepubliceerd in: (2012-09-01)

OA021-01. Construction and characterization of replication competent attenuated NYVAC-based vectors as potential HIV vaccines
door: Parrington M, et al.
Gepubliceerd in: (2009-10-01)

PedVacc Infant HIV-1 Vaccine Trials: First Stage Towards a Vaccine Against Breast Milk Transmission of HIV-1
door: Hanke, T, et al.
Gepubliceerd in: (2011)

Improved NYVAC-based vaccine vectors.
door: Karen V Kibler, et al.
Gepubliceerd in: (2011-01-01)

Immune Modulation of NYVAC-Based HIV Vaccines by Combined Deletion of Viral Genes that Act on Several Signalling Pathways
door: Carmen Elena Gómez, et al.
Gepubliceerd in: (2017-12-01)

PedVacc001:Safety and Immunogenicity of a Candidate HIV-1 Vaccine, MVA.HIVA, Administered to Healthy Gambian Infants Born to HIV-1/2-Uninfected Mothers
door: Afolabi, M, et al.
Gepubliceerd in: (2011)

P17-07. Insertion of a vaccinia virus host range (hr) gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens
door: Esteban M, et al.
Gepubliceerd in: (2009-10-01)

Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV/AIDS vaccine candidate NYVAC-C.
door: Beatriz Perdiguero, et al.
Gepubliceerd in: (2013-01-01)

PedVACC 001 and 002: building foundations for infant HIV-1 vaccine trials against breast milk transmission of HIV-1
door: Hanke, T
Gepubliceerd in: (2012)

Early and Long-Term HIV-1 Immunogenicity Induced in Macaques by the Combined Administration of DNA, NYVAC and Env Protein-Based Vaccine Candidates: The AUP512 Study
door: Beatriz Perdiguero, et al.
Gepubliceerd in: (2022-07-01)

rAd5 prime/NYVAC-B boost regimen is superior to NYVAC-B prime/rAd5 boost regimen for both response rates and magnitude of CD4 and CD8 T-cell responses
door: Bart P, et al.
Gepubliceerd in: (2012-09-01)

Phase I study of TNFalpha AutoVaccIne in patients with metastatic cancer.
door: Waterston, A, et al.
Gepubliceerd in: (2005)

THE EFFECT OF Theileria INFECTION ON THE IMMUNE RESPONSES OF CATTLE TO RINDERPEST VACC
door: M.G. Al-Gabban, et al.
Gepubliceerd in: (1996-06-01)

Primary HIV-1 subtype C infection in Ethiopia.
door: Rinke de Wit, T, et al.
Gepubliceerd in: (2002)

Mutations within the CD4-CDR-3-like loop allow replication in an immortalized T cell line of HIV type 1 viruses chimeric for envelope glycoproteins containing non-syncytium-inducing V3 loops.
door: Signoret, N, et al.
Gepubliceerd in: (1997)

The Vacc-SeqQC project: Benchmarking RNA-Seq for clinical vaccine studies
door: Johannes B. Goll, et al.
Gepubliceerd in: (2023-01-01)

Novel Adenovirus Vector-Based Vaccines for HIV
door: Letvin N, et al.
Gepubliceerd in: (2005-12-01)

Quality of T-cell responses versus reduction in viral load: results from an exploratory phase II clinical study of Vacc-4x, a therapeutic HIV vaccine
door: Ellefsen-Lavoie K, et al.
Gepubliceerd in: (2012-09-01)

Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses
door: Beatriz Perdiguero, et al.
Gepubliceerd in: (2019-12-01)

Corrigendum: The Vacc-SeqQC project: Benchmarking RNA-Seq for clinical vaccine studies
door: Johannes B. Goll, et al.
Gepubliceerd in: (2023-02-01)

Young carers in South Africa: tasks undertaken by children in households affected by HIV infection and other illness
door: Lane, T, et al.
Gepubliceerd in: (2014)

The Vaccination Concerns in COVID-19 Scale (VaCCS): Development and validation
door: Kyra Hamilton, et al.
Gepubliceerd in: (2022-01-01)

The Vaccination Concerns in COVID-19 Scale (VaCCS): Development and validation.
door: Kyra Hamilton, et al.
Gepubliceerd in: (2022-01-01)

Phase I of the DiaVACCS screening trial: Study design, methods, population demographics and baseline results
door: G Dreyer, et al.
Gepubliceerd in: (2022-07-01)

Intranasal administration of a therapeutic HIV vaccine (Vacc-4x) induces dose-dependent systemic and mucosal immune responses in a randomized controlled trial.
door: Kristin Brekke, et al.
Gepubliceerd in: (2014-01-01)

The role of CD4 in HIV binding and entry.
door: Sattentau, Q, et al.
Gepubliceerd in: (1993)

Characteristics of aquatic rescues undertaken by bystanders in Australia.
door: Robert W Brander, et al.
Gepubliceerd in: (2019-01-01)

HIV's gut feeling.
door: Sattentau, Q
Gepubliceerd in: (2008)

Decentralized Open Platform for Vaccination—A German Example: COVID-19-Vacc
door: Mirjana Radonjic-Simic, et al.
Gepubliceerd in: (2021-09-01)

Decentralized Open Platform for Vaccination—A German Example: COVID-19-Vacc
door: Mirjana Radonjic-Simic, et al.
Gepubliceerd in: (2021-08-01)

Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption.
door: Jürgen K Rockstroh, et al.
Gepubliceerd in: (2019-01-01)

Adequate vascular training can be undertaken without compromising patient care
door: Handa, A, et al.
Gepubliceerd in: (2001)

Viral Determinants of HIV-1 Macrophage Tropism
door: Christopher J. A. Duncan, et al.
Gepubliceerd in: (2011-11-01)

HIV infection and the immune system.
door: Sattentau, Q
Gepubliceerd in: (1989)

Neutralization of HIV-1 by antibody.
door: Sattentau, Q
Gepubliceerd in: (1996)

Influence of HLA-C expression level on HIV control.
door: Apps, R, et al.
Gepubliceerd in: (2013)